Biomarker Core

生物标志物核心

• 批准号: 10474591
• 负责人: Lynn Bekris
• 金额: $ 67.28万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10474591
• 关键词: Address; African American population; Alleles; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid beta-42; Biological Assay; Biological Markers; Blood; CCL2 gene; CXCL10 gene; Cataloging; Catalogs; Cerebrospinal Fluid; Clinic; Clinical Data; Collaborations; Collection; Communities; Consultations; DNA; Data; Data Set; Data Storage and Retrieval; Databases; Dementia; Dementia with Lewy Bodies; Diagnosis; Discrimination; Disease; Disease Progression; Ensure; Foundations; Future; Genetic; Genetic Diseases; Genetic Markers; Genotype; Goals; Heterogeneity; Human; Human Resources; Inflammation; Infrastructure; International; Light; Link; Medical Genetics; Medical center; Mentors; Mission; Molecular; Molecular Analysis; Molecular Genetics; Monitor; National Institute on Aging; Neurochip; Neurodegenerative Disorders; Other Genetics; Participant; Pathogenicity; Pathology; Plasma; Population; Population Heterogeneity; Process; Protein Analysis; Research; Research Personnel; Research Project Grants; Saliva; Sampling; Secure; Skin; Specimen; Symptoms; System; TREM2 gene; Time; Training; Translations; Underrepresented Populations; United States Department of Veterans Affairs; Universities; University Hospitals; Urine; alpha synuclein; apolipoprotein E-4; base; biobank; biological heterogeneity; biomarker discovery; chemokine; clinically relevant; cytokine; data exchange; data management; distributed data; education research; genetic analysis; genetic variant; imaging biomarker; improved; innovation; neurofilament; neuropathology; presenilin-1; programs; protein aggregation; protein biomarkers; repository; specific biomarkers; success; tau Proteins; tau-1; translational therapeutics

PROJECT SUMMARY The mission of the Biomarker Core (BC) is to support Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) research projects by collecting, storing, tracking, sharing, and analyzing biospecimens and associated clinical, genetic, and biomarker data. The collected clinical, genetic, and biomarker data on a variety of human biospecimens will contribute to the understanding of AD/ADRD underlying heterogeneity by cataloging the onset, progression, and disease symptoms of participant biospecimens currently stored in the Cleveland Alzheimer's Disease Research Center (CADRC) BC. This information will contribute to improving diagnosis in unique, understudied populations, as well as the population as a whole. Toward this mission, we previously established and integrated biospecimen collection and research collaborations between Case Western Reserve University, Cleveland Clinic, MetroHealth Systems, University Hospitals, and the Louis Stoke Cleveland VA Medical Center. The aims of the BC are to 1) Facilitate research by leveraging and expanding the CADRC BC infrastructure and biospecimens linked with participant clinical data in the integrated database and continue to include longitudinal biospecimen collection, 2) Provide basic biomarker characterization to facilitate AD/ADRD research, 3) Provide basic genetic characterization to facilitate AD/ADRD research, and 4) Distribute biospecimens to neurodegenerative disease consortiums and coordinating centers, as well as to internal and external investigators. Toward these aims, our team of experts will continue to contribute to biospecimen collection for the CADRC. The establishment of the CADRC BC has provided an essential infrastructure to facilitate and integrate the independent projects of unique and understudied populations, such as African Americans, as well as understudied neurodegenerative disorders, including atypical AD and dementia with Lewy bodies. Standard clinical data (the Uniform Data Set) from these diverse understudied populations will continue to be linked with generated biomarker and genetic data. Genetic and biomarker data linked to relevant clinical data in accordance with goals of the National Alzheimer's Project Act (NAPA) are shared with the scientific community including the Alzheimer's Disease Genetic Consortium (ADGC), National Alzheimer's Coordinating Center (NACC), and the National Institute on Aging Genetics of Alzheimer's Disease Data Storage (NIAGADS). The already established CCLRCBH-Biobank and our highly trained personnel has insured seamless creation of the CADRC BC. Importantly, the CADRC BC infrastructure is now in place to facilitate future innovative AD/ADRD research projects that enhances our understanding of the heterogeneity of AD/ADRD pathology.

项目概要 生物标记核心 (BC) 的使命是支持阿尔茨海默病 (AD) 和 AD 相关痴呆症 (AD/ADRD) 研究项目，通过收集、存储、跟踪、共享和分析生物样本和 相关的临床、遗传和生物标志物数据。收集的临床、遗传和生物标志物数据 各种人类生物样本将有助于理解 AD/ADRD 潜在的异质性 对当前存储在数据库中的参与者生物样本的发病、进展和疾病症状进行编目 克利夫兰阿尔茨海默病研究中心 (CADRC) BC。这些信息将有助于改善 对独特的、未充分研究的人群以及整个人群进行诊断。为了这个使命，我们 先前建立并整合了凯斯之间的生物样本收集和研究合作 西储大学、克利夫兰诊所、MetroHealth Systems、大学医院和路易斯斯托克医院 克利夫兰退伍军人医疗中心。 BC 的目标是 1) 通过利用和扩展来促进研究 CADRC BC 基础设施和生物样本与集成数据库中的参与者临床数据相关联 并继续包括纵向生物样本收集，2) 提供基本的生物标志物表征 促进 AD/ADRD 研究，3) 提供基本遗传特征以促进 AD/ADRD 研究，以及 4) 将生物样本分发给神经退行性疾病联盟和协调中心，以及 内部和外部调查员。为了实现这些目标，我们的专家团队将继续做出贡献 CADRC 的生物样本采集。 CADRC BC 的成立提供了必要的支持 促进和整合独特和未充分研究人群的独立项目的基础设施，例如 以及未充分研究的神经退行性疾病，包括非典型 AD 和 路易体痴呆。来自这些不同的被研究对象的标准临床数据（统一数据集） 人群将继续与生成的生物标志物和遗传数据联系起来。遗传和生物标志物数据 根据国家阿尔茨海默病项目法案 (NAPA) 的目标与相关临床数据相关联 与科学界共享，包括阿尔茨海默氏病遗传联盟 (ADGC)、国家 阿尔茨海默病协调中心 (NACC) 和国家阿尔茨海默病衰老遗传学研究所 数据存储（NIAGADS）。已经建立的 CCLRCBH-Biobank 和我们训练有素的人员已经 确保 CADRC BC 的无缝创建。重要的是，CADRC BC 基础设施现已到位， 促进未来创新的 AD/ADRD 研究项目，增强我们对异质性的理解 AD/ADRD 病理学。